Legion logo
Sign in

SWORD Health

SH
HealthTechHealthTechHardwareNew YorkFounded 2015Website
#327 by valuationHype56

Sword Health sells an AI Care platform that pairs its own AI with licensed clinicians across four areas: musculoskeletal and pain care through Thrive and Move, pelvic and women's health through Bloom, mental health through Mind, and cardiometabolic care through Pulse. Members use an app with motion-tracking sensors to do physical therapy at home, and the programs are sold to employers and health plans. In July 2026 it agreed to acquire Headspace for a reported $300 million; the deal awaits regulatory clearance.

Founded by Virgílio Bento (Co-founder, CEO), Márcio Colunas (Co-founder, Chief Scientific Officer), André Eiras dos Santos (Co-founder), Fernando Correia (Co-founder), Ivo Gabriel (Co-founder)

Blended valuation$2.5B$2.4B secondary
Valuation history
Weekly blended valuation with priced funding rounds marked on the timeline.
$4.3B
blended valuationfunding round
May 31, 2021$0Oct 5, 2026
All rounds
10 funding rounds, newest first.
RoundAnnouncedRaisedPost-money
Series FJun 17, 2025$40M$4B
Series EJun 4, 2024$30M$3B
RoundJun 4, 2024$130M—
Series DNov 22, 2021$163M$2B
Series CJun 30, 2021$85M$485M
Join Legion to view all 10 rounds.Sign in to Legion
Investors
29 investors across all rounds.
  • KV
    Khosla Ventures
  • GC
    General Catalyst
  • SV
    Sapphire Ventures
  • FF
    Founders Fund
  • BO
    Bond
  • CV
    Comcast Ventures
  • LG
    Lachy Groom
  • LO
    LocalGlobe
  • SV
    Sozo Ventures
  • TC
    Transformation Capital
Only Legion members can view the full investor roster. Sign in to Legion
Secondary market activity
Recent buy and sell interest for SWORD Health shares on the secondary market.
KindImplied valuationPrice / shareDate
Quote$1.9B$30.00Sep 23, 2026
Quote$1.9B$30.00Sep 22, 2026
Ask$1.9B$30.00Sep 14, 2026

Invest in the private markets on Legion

Registered users see full trading activity, every investor, rankings, and live deals.

Get started

Data as of Oct 16, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.